Literature DB >> 8319172

Prognostic factors of malignant mesothelioma of the pleura.

V De Pangher Manzini1, A Brollo, S Franceschi, M De Matthaeis, R Talamini, C Bianchi.   

Abstract

BACKGROUND: Pleural mesothelioma is a rare condition with a poor prognosis. The area of Monfalcone, North East Italy, provided a unique opportunity to study the disease because of its past heavy exposure to asbestos in local harbors and shipyards and its high necropsy rates.
METHODS: The effects of various patient and tumor characteristics on survival were evaluated in 80 patients (73 males and 7 females; median age, 69) of histologically or cytologically confirmed malignant mesothelioma of the pleura. These patients were examined between October 1979 and October 1991 at the General Hospital of Monfalcone in the Friuli-Venezia Giulia region. Substantial exposures to asbestos were identified in 79 patients.
RESULTS: Median survival rate was 13 months (range, 2-44 months), and overall 2- and 5-year survival rates were 23% and 0%, respectively. The factors that exerted a significant favorable influence on survival were as follows: (1) age younger than 65; (2) performance status less than or equal to one; (3) lack of less than or equal to 10% weight loss at any time; (4) Stages I and II; (5) epithelial or mixed histologic type; and (6) presence of pleural fluid with mesothelial cells but without neoplastic cells. When these factors were introduced in a Cox proportional hazard model, age, stage, and histologic type were the only independent prognostic factors. The increased hazards for patients, ages 65-74 (as compared to < 65), and for patients with sarcomatous histologic type (as compared to epithelial type) were 2.6 (95% confidence interval [CI], 1.2-5.7) and 4.5 (95% CI, 1.6-12.8).
CONCLUSIONS: Survival rate in 24 untreated patients (median, 10 months) and 56 patients variously treated (median, 15 months) did not differ significantly. The availability of large portions of tumor specimens for histologic examinations in 77 of 80 patients, chiefly from high necropsy rate, strengthens the value of the present analysis of prognostic factors.

Entities:  

Mesh:

Year:  1993        PMID: 8319172     DOI: 10.1002/1097-0142(19930715)72:2<410::aid-cncr2820720216>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems.

Authors:  J G Edwards; K R Abrams; J N Leverment; T J Spyt; D A Waller; K J O'Byrne
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

2.  Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma.

Authors:  K Segers; H Backhovens; S K Singh; J De Voecht; M Ramael; C Van Broeckhoven; E Van Marck
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

3.  Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.

Authors:  Raffit Hassan; Hedy L Kindler; Thierry Jahan; Lyudmila Bazhenova; Martin Reck; Anish Thomas; Ira Pastan; Jeff Parno; Daniel J O'Shannessy; Penny Fatato; Julia D Maltzman; Bruce A Wallin
Journal:  Clin Cancer Res       Date:  2014-09-17       Impact factor: 12.531

4.  Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection.

Authors:  Anubha Gupta; Ziad Hussein; Raffit Hassan; Jason Wustner; Julia D Maltzman; Bruce A Wallin
Journal:  Cancer Chemother Pharmacol       Date:  2016-02-22       Impact factor: 3.333

5.  Factors that impact susceptibility to fiber-induced health effects.

Authors:  Jennifer E Below; Nancy J Cox; Naomi K Fukagawa; Ari Hirvonen; Joseph R Testa
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

6.  Epidemiology of mesothelioma in Egypt. A ten-year (1998-2007) multicentre study.

Authors:  Yosri Akl; Safy Kaddah; Ahmed Abdelhafeez; Randa Salah; Mohamed Lotayef
Journal:  Arch Med Sci       Date:  2010-12-29       Impact factor: 3.318

7.  A Subset of Malignant Mesothelioma Tumors Retain Osteogenic Potential.

Authors:  S M Lansley; B Pedersen; C Robinson; R G Searles; G Sterrett; I van Bruggen; R A Lake; S E Mutsaers; C M Prêle
Journal:  Sci Rep       Date:  2016-11-25       Impact factor: 4.379

8.  Clinical significance of serum CA125 in diffuse malignant mesothelioma.

Authors:  Xu Cheng; Hong-Feng Gou; Ji-Yan Liu; De-Yun Luo; Meng Qiu
Journal:  Springerplus       Date:  2016-03-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.